Industry
Handok-Genexine’s long-acting growth hormone gets orphan drug status in Korea
March 8, 2024
South Korean pharmaceutical company Handok announced Friday that GX-H9, a long-acting recombinant human growth hormone it co-developed with Genexine, has won orphan drug designation from the country's Ministry of Food and Drug Safety. Handok said the designation for GX-H9, which it received on Monday this week, will help the company speed up the launch of the medicine. In Korea, when a drug qualifies for the orphan drug designation, the drug is eligible for conditional approval based on res